Less Ads, More Data, More Tools Register for FREE

Pin to quick picksEkf Diagnostics Regulatory News (EKF)

Share Price Information for Ekf Diagnostics (EKF)

Share Price is delayed by 15 minutes
Get Live Data
26.40    0.00 (0.00%)
Bid:
26.10
Ask:
27.40
Spread: 1.30 (4.981%)
Market Cap: £113.65m
EKF Live PriceLast checked at - London Stock Exchange

Intraday Ekf Diagnostics Share Chart

Board Changes

27 Apr 2026 07:00

RNS Number : 9952B
EKF Diagnostics Holdings PLC
27 April 2026
 

 

EKF Diagnostics Holdings plc

("EKF" or the "Company")

 

Board Changes

Appointment of Chief Financial Officer

 

EKF Diagnostics Holdings plc (AIM: EKF), the AIM-quoted global diagnostics business, announces the appointment of Helen Jones FCA as Chief Financial Officer ("CFO"). Helen will join the Board and assume the role of CFO with immediate effect.

 

Helen Jones is an experienced CFO with over 20 years' experience leading finance, operations, and strategic transactions in high-growth, technology-driven AIM listed businesses.

 

Helen joins EKF from Surgical Science, a leading provider of medical simulation solutions, where she has assumed a senior Group-level role following its acquisition of Intelligent Ultrasound Group plc in February 2025, with responsibility spanning post-acquisition integration and operational cost reduction, Group statutory reporting, and sustainability leadership. Prior to the acquisition, Helen spent five years as CFO of Intelligent Ultrasound Group plc, an AIM-listed company supplying simulation and AI-based ultrasound training solutions to the healthcare sector. During her tenure, Helen led two successful equity placings to fund growth and innovation, played a central role in both the £40.6 million divestment of its Clinical AI division to GE Healthcare and the subsequent sale of the Simulation business to Surgical Science.

 

Before joining Intelligent Ultrasound, Helen held a senior finance role within AIM-listed oil and exploration company Amerisur Resources plc and prior to that spent 11 years in various senior financial positions at Tata Steel Europe. Helen is a fellow of the Institute of Chartered Accountants in England and Wales having trained and qualified with PwC in 2004.

 

Helen succeeds Stephen Young, who is retiring from the Board. Steve will be available to support Helen to ensure a smooth handover but will step down from the Board with immediate effect. The Board would like to extend its sincere thanks to Steve for his financial stewardship since joining the Company in September 2023 and wishes him well in his retirement.

 

 

Commenting, Gavin Jones, Chief Executive Officer, said: "We are delighted to welcome Helen to the EKF team at a key time as we execute on our five-year development plan for accelerated growth. Helen's track record in listed healthcare technology businesses, her experience executing complex transactions, and her capital markets expertise make her an excellent fit for EKF as we accelerate our five-year plan. Her appointment reflects our commitment to building a leadership team capable of delivering our ambitious growth targets."

 

Additional Disclosures Required under the AIM Rules for Companies

The following additional information is provided with regards to the appointment of Helen Mary Kinsey Jones (aged 47) in accordance with AIM Rule 17 and Schedule 2(g) of the AIM Rules for Companies:

 

Current Directorships/partnerships

Directorships/partnerships within the last five years:

None

IML Finance Limited

Intelligent Ultrasound Innovations Limited

Intelligent Ultrasound Limited

Intelligent Ultrasound North America Inc

Inventive Medical Limited

Medaphor International Limited

Surgical Science UK Limited

Surgical Science UK Holdings Limited

 

Helen does not hold any shares or options in the Company.

 

There are no further disclosures required under Rule 17 and Schedule 2(g) of the AIM Rules for Companies.

 

The person responsible for arranging the release of this Announcementon behalf of the Company is Gavin Jones, Chief Executive Officer.

 

EKF Diagnostics Holdings plc

www.ekfdiagnostics.com

Julian Baines, Executive Chair

 via Walbrook PR

Gavin Jones, Chief Executive Officer

 

Singer Capital Markets (Nominated Adviser & Broker)

Tel: +44 (0)20 7496 3000

Phil Davies / Patrick Weaver

Walbrook PR Limited

Tel: +44 (0)20 7933 8780 or ekf@walbrookpr.com

Paul McManus / Alice Woodings 

Mob: +44 (0)7980 541 893 / +44 (0)7407 804 654

 

 

 

About EKF Diagnostics Holdings plc (www.ekfdiagnostics.com)

 

EKF is an AIM-listed global diagnostics business focussed on:

 

Point-of-Care analysers in the key areas of Hematology and Diabetes 

Life Sciences services provide specialist manufacture of enzymes and custom products for use in diagnostic, food and industrial applications.

 

EKF has headquarters in Penarth (near Cardiff) and operates five manufacturing sites across the US and Germany, selling into over 120 countries world-wide.

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
BOASEAESMEMSEFL
Date   Source Headline
24th Nov 202511:47 amRNSShare Buyback
19th Nov 20253:41 pmRNSShare Buyback
17th Nov 20252:12 pmRNSShare Buyback
4th Nov 20251:54 pmRNSTotal Voting Rights
3rd Nov 202510:19 amRNSShare Buyback
31st Oct 20251:02 pmRNSShare Buyback
30th Oct 202512:55 pmRNSShare Buyback
29th Oct 202510:59 amRNSShare Buyback
28th Oct 202511:00 amRNSShare Buyback
27th Oct 202510:25 amRNSShare Buyback
24th Oct 202511:10 amRNSShare Buyback
23rd Oct 202510:10 amRNSShare Buyback
21st Oct 20253:10 pmRNSShare Buyback & Extension of Buyback Programme
20th Oct 202512:24 pmRNSShare Buyback (Replacement)
20th Oct 202511:36 amRNSShare Buyback
17th Oct 20257:00 amRNSShare Buyback
15th Oct 202512:30 pmRNSShare Buyback
19th Sep 20254:25 pmRNSHolding(s) in Company
16th Sep 20257:15 amRNSLong Term Incentive Plan
16th Sep 20257:00 amRNSHalf-year Report
10th Sep 20257:00 amRNSNotice of interim results
26th Aug 20257:00 amRNSHematology contracts signed worth EUR 4.65m
28th Jul 20257:00 amRNSH1 2025 Trading Update
25th Jun 202512:00 pmRNSCancellation of Treasury Shares & TVR
17th Jun 20255:24 pmRNSHolding(s) in Company
2nd Jun 20257:00 amRNSTotal Voting Rights
21st May 20257:00 amRNSAdditional Share Buyback Programme
20th May 20252:41 pmRNSResult of AGM and Voting Results
20th May 20257:00 amRNSAGM Statement
13th May 20257:00 amRNSShare Buyback & Completion of Share Buyback Prog.
9th May 20251:42 pmRNSShare Buyback
8th May 20259:11 amRNSShare Buyback
6th May 20253:55 pmRNSShare Buyback
29th Apr 20257:00 amRNSShare Buyback
28th Apr 20257:00 amRNSPosting of AR&A & Notice of AGM
9th Apr 20257:00 amRNSShare Buyback
8th Apr 20257:00 amRNSShare Buyback
7th Apr 20252:58 pmRNSShare Buyback
7th Apr 20257:00 amRNSShare Buyback
2nd Apr 20257:00 amRNSShare Buyback
1st Apr 20257:00 amRNSShare Buyback
26th Mar 20257:00 amRNSDirector/PDMR Shareholding
25th Mar 20257:00 amRNSAppointment of CEO
25th Mar 20257:00 amRNSFull year results
6th Mar 20257:00 amRNSNotice of Results & Investor Presentations
7th Feb 20253:04 pmRNSHolding(s) in Company
6th Feb 202511:34 amRNSHolding(s) in Company
29th Jan 20257:00 amRNSFY 2024 Trading Update
17th Sep 20247:00 amRNSHalf-year Report
3rd Sep 20247:00 amRNSNotice of Results and Investor Presentation

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.